Hudson Bay Capital Management LP Takes Position in UroGen Pharma Ltd. (NASDAQ:URGN)

Hudson Bay Capital Management LP acquired a new stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 233,322 shares of the company's stock, valued at approximately $2,485,000. Hudson Bay Capital Management LP owned approximately 0.99% of UroGen Pharma at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the business. Acorn Capital Advisors LLC bought a new stake in UroGen Pharma in the 4th quarter valued at approximately $16,149,000. Nantahala Capital Management LLC bought a new stake in UroGen Pharma in the 4th quarter valued at approximately $14,608,000. Silverarc Capital Management LLC lifted its stake in UroGen Pharma by 24.3% in the 4th quarter. Silverarc Capital Management LLC now owns 1,120,473 shares of the company's stock valued at $11,933,000 after acquiring an additional 219,344 shares in the last quarter. Rosalind Advisors Inc. bought a new stake in UroGen Pharma in the 4th quarter valued at approximately $9,266,000. Finally, DAFNA Capital Management LLC lifted its stake in UroGen Pharma by 7.3% in the 4th quarter. DAFNA Capital Management LLC now owns 492,515 shares of the company's stock valued at $5,245,000 after acquiring an additional 33,600 shares in the last quarter. Institutional investors own 91.29% of the company's stock.

Analyst Ratings Changes

Several research analysts have weighed in on URGN shares. Guggenheim reaffirmed a "buy" rating on shares of UroGen Pharma in a research report on Tuesday, April 29th. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price target on shares of UroGen Pharma in a research report on Tuesday. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price target on shares of UroGen Pharma in a research report on Thursday, May 8th. The Goldman Sachs Group lowered their price target on UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. Finally, LADENBURG THALM/SH SH started coverage on UroGen Pharma in a research report on Wednesday, February 19th. They set a "buy" rating and a $31.00 price target on the stock. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $32.86.

UroGen Pharma Stock Performance

Shares of URGN stock traded down $2.54 during trading on Friday, reaching $7.31. 9,587,659 shares of the company's stock were exchanged, compared to its average volume of 585,382. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The stock has a market capitalization of $337.04 million, a PE ratio of -2.32 and a beta of 0.66. UroGen Pharma Ltd. has a twelve month low of $6.46 and a twelve month high of $20.70. The firm's fifty day moving average price is $10.59 and its 200-day moving average price is $10.90.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The company had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. As a group, sell-side analysts anticipate that UroGen Pharma Ltd. will post -3.12 EPS for the current year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.